BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021;74:2342-52. [PMID: 33739462 DOI: 10.1002/hep.31819] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 44.5] [Reference Citation Analysis]
Number Citing Articles
1 Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin Liver Dis 2023;27:85-102. [PMID: 36400469 DOI: 10.1016/j.cld.2022.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Eghbali M, Haber ZM, Srinivasa RN, Padia SA. Complications of 90Y Radioembolization Treatment for Liver Tumors. Digestive Disease Interventions 2023. [DOI: 10.1055/s-0043-1760730] [Reference Citation Analysis]
3 Criss CR, Makary MS. Salvage locoregional therapies for recurrent hepatocellular carcinoma. World J Gastroenterol 2023; 29(3): 413-424 [PMID: 36688022 DOI: 10.3748/wjg.v29.i3.413] [Reference Citation Analysis]
4 Hamm CA, Busch F, Pöhlmann A, Shewarega A, He Y, Schmidt R, Xu H, Wieners G, Gebauer B, Savic LJ. Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma. J Hepatocell Carcinoma 2023;10:27-42. [PMID: 36660411 DOI: 10.2147/JHC.S391537] [Reference Citation Analysis]
5 Lee IJ, Chun HJ, Chung JW. 2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Transarterial Therapy of Hepatocellular Carcinoma: What's New? Korean J Radiol 2023;24:6-9. [PMID: 36606613 DOI: 10.3348/kjr.2022.0510] [Reference Citation Analysis]
6 Salerno KE, Roy S, Ribaudo C, Fisher T, Patel RB, Mena E, Escorcia FE. A Primer on Radiopharmaceutical Therapy. Int J Radiat Oncol Biol Phys 2023;115:48-59. [PMID: 35970373 DOI: 10.1016/j.ijrobp.2022.08.010] [Reference Citation Analysis]
7 Cianni R, Riu P, de Rubeis G, Ventroni G. Endovascular Treatments of Hepatocellular Carcinoma. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_9] [Reference Citation Analysis]
8 Salem R, Padia SA, Lam M, Chiesa C, Haste P, Sangro B, Toskich B, Fowers K, Herman JM, Kappadath SC, Leung T, Sze DY, Kim E, Garin E. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2023;50:328-43. [PMID: 36114872 DOI: 10.1007/s00259-022-05956-w] [Reference Citation Analysis]
9 Hamad A, Aziz H, Kamel IR, Diaz DA, Pawlik TM. Yttrium-90 Radioembolization: Current Indications and Outcomes. J Gastrointest Surg 2022. [PMID: 36547759 DOI: 10.1007/s11605-022-05559-8] [Reference Citation Analysis]
10 Mosconi C, Cappelli A, Pettinato C, Cocozza MA, Vara G, Terzi E, Morelli MC, Lodi Rizzini E, Renzulli M, Modestino F, Serenari M, Bonfiglioli R, Calderoni L, Tabacchi E, Cescon M, Morganti AG, Trevisani F, Piscaglia F, Fanti S, Strigari L, Cucchetti A, Golfieri R. Improved Survival after Transarterial Radioembolisation for Hepatocellular Carcinoma Gives the Procedure Added Value. J Clin Med 2022;11. [PMID: 36556085 DOI: 10.3390/jcm11247469] [Reference Citation Analysis]
11 Chiu AM, Savoor R, Gordon AC, Riaz A, Sato KT, Hohlastos E, Salem R, Lewandowski RJ. Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies. J Vasc Interv Radiol 2022:S1051-0443(22)01418-X. [PMID: 36526074 DOI: 10.1016/j.jvir.2022.12.021] [Reference Citation Analysis]
12 Da BL, He AR, Shetty K, Suchman KI, Yu H, Lau L, Wong LL, Rabiee A, Amdur RL, Crawford JM, Fox SS, Grimaldi GM, Shah PK, Weinstein J, Bernstein D, Satapathy SK, Chambwe N, Xiang X, Mishra L. Pathogenesis to management of hepatocellular carcinoma. Genes Cancer 2022;13:72-87. [DOI: 10.18632/genesandcancer.226] [Reference Citation Analysis]
13 Gosztonyi B, Pestalozzi B, Kenkel D, Engel-Bicik I, Kaufmann PA, Treyer V, Siebenhüner AR. A descriptive analysis of the characteristics, treatment response and prognosis of hepatic dominant solid tumors undergoing selective internal radiation therapy (SIRT). J Gastrointest Oncol 2022;13:3240-53. [PMID: 36636090 DOI: 10.21037/jgo-22-122] [Reference Citation Analysis]
14 Bekki Y, Mahamid A, Lewis S, Ward SC, Simpson W, Argiriadi P, Kamath A, Facciuto L, Patel RS, Kim E, Schiano TD, Facciuto ME. Radiological and pathological assessment with EOB-MRI after Y90 radiation lobectomy prior to liver resection for hepatocellular carcinoma. HPB (Oxford) 2022;24:2185-92. [PMID: 36085263 DOI: 10.1016/j.hpb.2022.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tortajada P, Doamba R, Cano L, Ghallab M, Allard MA, Ciacio O, Pittau G, Salloum C, Cherqui D, Adam R, Sa Cunha A, Azoulay D, Pascale A, Vibert E, Golse N. Resectable and transplantable hepatocellular carcinoma: Integration of liver stiffness assessment in the decision-making algorithm. Surgery 2022;172:1704-11. [PMID: 36241470 DOI: 10.1016/j.surg.2022.08.012] [Reference Citation Analysis]
16 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2022;23:1126-240. [PMID: 36447411 DOI: 10.3348/kjr.2022.0822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Allignet B, Pradat P, Mornex F, Izarn F, Rode A, Mabrut J, Mohkam K, Merle P. Surgical resection versus transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma. Strahlenther Onkol 2022. [DOI: 10.1007/s00066-022-02022-0] [Reference Citation Analysis]
18 Mena E, Shih J, Chung J, Jones J, Rabiee A, Monge C, Turkbey B, Lindenberg L, Salerno KE, Kassin M, Wood B, Hernandez J, Maass-moreno R, Saboury B, Jakhete N, Molitoris JK, Unger KR, Choyke PL, Escorcia FE. Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma. PLoS ONE 2022;17:e0277407. [DOI: 10.1371/journal.pone.0277407] [Reference Citation Analysis]
19 Patel MV, Mcniel D, Brunson C, Kuo PH, Hennemeyer CT, Woodhead G, Mcgregor H. Prior ablation and progression of disease correlate with higher tumor-to-normal liver 99mTc-MAA uptake ratio in hepatocellular carcinoma. Abdom Radiol 2022. [DOI: 10.1007/s00261-022-03718-8] [Reference Citation Analysis]
20 Prince DS, Schlaphoff G, Davison SA, Huo YR, Xiang H, Chan MV, Lee AU, Thailakanathan C, Jebeili H, Rogan C, Al-Omary A, Gupta S, Lockart I, Tiwari N, Clark-Dickson M, Hillhouse JW, Laube R, Chang J, Nguyen V, Danta M, Cheng R, Strasser SI, Zekry A, Levy MT, Chan C, Liu K. Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study. J Gastroenterol Hepatol 2022;37:2173-81. [PMID: 36031345 DOI: 10.1111/jgh.15986] [Reference Citation Analysis]
21 Di Martino M, Vitale A, Ferraro D, Maniscalco M, Pisaniello D, Arenga G, Falaschi F, Terrone A, Iacomino A, Galeota Lanza A, Esposito C, Cillo U, Vennarecci G. Downstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes. Cancers 2022;14:5102. [DOI: 10.3390/cancers14205102] [Reference Citation Analysis]
22 Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022;400:1345-62. [PMID: 36084663 DOI: 10.1016/S0140-6736(22)01200-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
23 Horvat N, de Oliveira AI, Clemente de Oliveira B, Araujo-Filho JAB, El Homsi M, Elsakka A, Bajwa R, Martins GLP, Elsayes KM, Menezes MR. Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists. Radiographics 2022;42:1670-89. [PMID: 36190854 DOI: 10.1148/rg.220022] [Reference Citation Analysis]
24 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. [PMID: 36263666 DOI: 10.3350/cmh.2022.0294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
25 Garcia-Monaco RD, Chung JW, Vilgrain V, Bouattour M, Covey AM. Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America. Br J Radiol 2022;95:20220179. [PMID: 35848758 DOI: 10.1259/bjr.20220179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Goyal P, Salem R, Mouli SK. Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. Br J Radiol 2022;95:20220379. [PMID: 35867889 DOI: 10.1259/bjr.20220379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 de Baere T, Crocetti L. Radioembolization: Same Player Shoots Again. Cardiovasc Intervent Radiol 2022. [PMID: 36123447 DOI: 10.1007/s00270-022-03269-x] [Reference Citation Analysis]
28 Fung J, DiSabato D, Liao CY, Ahmed O, Pillai A. Perspective: Advances in liver transplantation for hepatocellular carcinoma - A prototype for transplant oncology. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00204-1. [PMID: 36163102 DOI: 10.1016/j.hbpd.2022.09.003] [Reference Citation Analysis]
29 Orcajo Rincón J, Reguera Berenguer L, Alonso Farto J. ¿Son reproducibles los resultados de la segmentectomía rádica en el carcinoma hepatocelular? ¿Cuáles son los factores que garantizan el éxito? Revista Española de Medicina Nuclear e Imagen Molecular 2022;41:273-274. [DOI: 10.1016/j.remn.2022.07.004] [Reference Citation Analysis]
30 Orcajo Rincón J, Reguera Berenguer L, Alonso Farto JC. Are the radiation segmentectomy results in hepatocellular carcinoma reproducible? What factors guarantee success? Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2022;41:273-274. [DOI: 10.1016/j.remnie.2022.07.008] [Reference Citation Analysis]
31 Rincón JO, Regi AR, Peña AM, Berenguer LR, Leyte MG, Martín LC, Santa JAGDL, Boyra ME, Ruiz CG, Rodriguez AC, Farto JCA. Maximum Tumor Absorbed Dose Measured by Voxel-Based Multicompartmental Dosimetry as a Response Predictor in Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcioma.. [DOI: 10.21203/rs.3.rs-1860740/v1] [Reference Citation Analysis]
32 Sidali S, Trépo E, Sutter O, Nault JC. New concepts in the treatment of hepatocellular carcinoma. United European Gastroenterol J 2022. [PMID: 35975347 DOI: 10.1002/ueg2.12286] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Brown AM, Kassab I, Massani M, Townsend W, Singal AG, Soydal C, Moreno-Luna L, Roberts LR, Chen VL, Parikh ND. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Cancer Med 2022. [PMID: 35943116 DOI: 10.1002/cam4.5125] [Reference Citation Analysis]
34 Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Philipp A, Berg T, Klümpen HJ, Benckert J, Pech M, Gasbarrini A, Amthauer H, Bartenstein P, Sangro B, Malfertheiner P, Ricke J, Seidensticker M. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib. Eur J Nucl Med Mol Imaging 2022. [PMID: 35916920 DOI: 10.1007/s00259-022-05920-8] [Reference Citation Analysis]
35 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2022;42:2067-79. [PMID: 34515412 DOI: 10.1111/liv.15052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
36 da Fonseca LG, Araujo RLC. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. World J Gastroenterol 2022; 28(28): 3573-3585 [DOI: 10.3748/wjg.v28.i28.3573] [Reference Citation Analysis]
37 Malone CD, Egbulefu C, Zheleznyak A, Polina J, Karmakar P, Black K, Shokeen M, Achilefu S. Activation of nano-photosensitizers by Y-90 microspheres to enhance oxidative stress and cell death in hepatocellular carcinoma. Sci Rep 2022;12:12748. [PMID: 35882949 DOI: 10.1038/s41598-022-17185-0] [Reference Citation Analysis]
38 Sharma R, Slater S, Evans J, Martinez M, Ward C, Izadi H, Wernig F, Thomas R. ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs). BMC Cancer 2022;22:800. [PMID: 35858849 DOI: 10.1186/s12885-022-09859-9] [Reference Citation Analysis]
39 Pérez-López A, Martín-Sabroso C, Gómez-Lázaro L, Torres-Suárez AI, Aparicio-Blanco J. Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation. Acta Biomater 2022:S1742-7061(22)00412-3. [PMID: 35842035 DOI: 10.1016/j.actbio.2022.07.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Chin R, Bommireddy A, Fraum TJ, Ludwig DR, Huang Y, Zoberi JE, Garcia-ramirez JL, Maughan NM, Chapman W, Korenblat K, Henke LE, Kim H, Badiyan SN. Clinical Outcomes of Patients With Unresectable Primary Liver Cancer Treated With Yttrium-90 Radioembolization With an Escalated Dose. Advances in Radiation Oncology 2022;7:100948. [DOI: 10.1016/j.adro.2022.100948] [Reference Citation Analysis]
41 Rothenberger NJ, Yu Q, Ramasamy SK, Van Ha T, Zangan S, Navuluri R, Ahmed O. Segmental Yttrium-90 Radioembolization as an Initial Treatment for Solitary Unresectable HCC. The Arab Journal of Interventional Radiology 2022;06:056-062. [DOI: 10.1055/s-0042-1758698] [Reference Citation Analysis]
42 Reeves HL, Reicher J, Priona G, Manas DM, Littler P. Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England. Frontline Gastroenterol 2023;14:45-51. [PMID: 36561784 DOI: 10.1136/flgastro-2022-102137] [Reference Citation Analysis]
43 Aryan M, Altshuler E, Qian X, Zhang W. Treatment of Advanced Hepatocellular Carcinoma. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.99837] [Reference Citation Analysis]
44 Roa D, Kuo J, Moyses H, Taborek P, Tajima T, Mourou G, Tamanoi F. Fiber-Optic Based Laser Wakefield Accelerated Electron Beams and Potential Applications in Radiotherapy Cancer Treatments. Photonics 2022;9:403. [DOI: 10.3390/photonics9060403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. World J Hepatol 2022; 14(5): 885-895 [DOI: 10.4254/wjh.v14.i5.885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ramtohul T, Vilgrain V, Soubrane O, Bouattour M, Luciani A, Kobeiter H, Mule S, Tacher V, Laurent A, Amaddeo G, Regnault H, Bulsei J, Nault J, Nahon P, Durand-zaleski I, Seror O. Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers 2022;14:2634. [DOI: 10.3390/cancers14112634] [Reference Citation Analysis]
47 Hendriks P, Rietbergen DDD, van Erkel AR, Coenraad MJ, Arntz MJ, Bennink RJ, Braat AE, Crobach ASLP, van Delden OM, van der Hulle T, Klümpen HJ, van der Meer RW, Nijsen JFW, van Rijswijk CSP, Roosen J, Ruijter BN, Smit F, Stam MK, Takkenberg RB, Tushuizen ME, van Velden FHP, de Geus-Oei LF, Burgmans MC; Dutch Hepatocellular Cholangiocarcinoma Group. Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients-A Dose-Finding Study (HORA EST HCC Trial). Cardiovasc Intervent Radiol 2022. [PMID: 35618860 DOI: 10.1007/s00270-022-03162-7] [Reference Citation Analysis]
48 Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Lewandowski RJ, Salem R. Implementation of radiation segmentectomy for early-stage hepatocellular carcinoma. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00161-3] [Reference Citation Analysis]
50 Hallemeier CL, Apisarnthanarax S, Dawson LA. BCLC 2022 update: Important advances, but missing external beam radiotherapy. J Hepatol 2022;76:1237-9. [PMID: 34990748 DOI: 10.1016/j.jhep.2021.12.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
51 Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, Knešaurek K, Fischman A, Patel R, Nowakowski S, Llovet J, Taouli B, Lookstein R. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00091-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Becker LS, Wacker FK, Hinrichs JB. Diagnostik und intraarterielle Therapien primärer Lebertumoren. Onkologe 2022;28:308-317. [DOI: 10.1007/s00761-022-01117-8] [Reference Citation Analysis]
53 d'Abadie P, Walrand S, Lhommel R, Hesse M, Borbath I, Jamar F. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Curr Oncol 2022;29:2422-34. [PMID: 35448170 DOI: 10.3390/curroncol29040196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Mauro E, Forner A. Barcelona Clinic Liver Cancer 2022 update: Linking prognosis prediction and evidence-based treatment recommendation with multidisciplinary clinical decision-making. Liver Int 2022;42:488-91. [PMID: 35194931 DOI: 10.1111/liv.15180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76:681-93. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 302] [Cited by in F6Publishing: 279] [Article Influence: 302.0] [Reference Citation Analysis]
56 Guiu B, Garin E, Allimant C, Edeline J, Salem R. TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. Cardiovasc Intervent Radiol 2022. [PMID: 35149884 DOI: 10.1007/s00270-022-03072-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Young S, Ragulojan R, Chen T, Owen J, D'souza D, Sanghvi T, Golzarian J, Flanagan S. Dynamic Lymphocyte Changes Following Transarterial Radioembolization: Association with Normal Liver Dose and Effect on Overall Survival. JHC 2022;Volume 9:29-39. [DOI: 10.2147/jhc.s350219] [Reference Citation Analysis]
58 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
59 Ponziani FR, Santopaolo F, Posa A, Pompili M, Tanzilli A, Maestri M, Pallozzi M, Ibba F, Manfredi R, Gasbarrini A, Iezzi R. SIRT in 2025. Cardiovasc Intervent Radiol 2022;45:1622-33. [PMID: 35941244 DOI: 10.1007/s00270-022-03228-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bertolet A, Wehrenberg-Klee E, Bobić M, Grassberger C, Perl J, Paganetti H, Schuemann J. Pre- and post-treatment image-based dosimetry in(90)Y-microsphere radioembolization using the TOPAS Monte Carlo toolkit. Phys Med Biol 2021;66. [PMID: 34915451 DOI: 10.1088/1361-6560/ac43fd] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Salem R, Gabr A. Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. J Nucl Med 2022;63:57-8. [PMID: 34916247 DOI: 10.2967/jnumed.121.262917] [Reference Citation Analysis]
62 Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, Herrmann K, Brown E, Zuckerman D, Wilson G, Kim TY, Weaver A, Ross P, Harris WP, Graham J, Mills J, Yubero Esteban A, Johnson MS, Sofocleous CT, Padia SA, Lewandowski RJ, Garin E, Sinclair P, Salem R; EPOCH Investigators. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol 2021;39:3897-907. [PMID: 34541864 DOI: 10.1200/JCO.21.01839] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
63 Keane G, Lam M, de Jong H. Beyond the MAA-Y90 Paradigm: The Evolution of Radioembolization Dosimetry Approaches and Scout Particles. Semin Intervent Radiol 2021;38:542-53. [PMID: 34853500 DOI: 10.1055/s-0041-1736660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Ku E, Yeakel J, Gan M, Ahmed F, Harris JP, Kuo JV, Wolf R, Fernando DM, Seyedin SN. The Role of Ablative Radiotherapy to Liver Oligometastases from Colorectal Cancer. Curr Colorectal Cancer Rep 2021;17:103-12. [DOI: 10.1007/s11888-021-00472-9] [Reference Citation Analysis]
65 Iñarrairaegui M, Sangro B. Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next? Hepatology 2021;74:2333-5. [PMID: 34245592 DOI: 10.1002/hep.32054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Kim GM. Superselective transarterial radioembolization for the treatment of hepatocellular carcinoma. Int J Gastrointest Interv 2021;10:165-8. [DOI: 10.18528/ijgii210051] [Reference Citation Analysis]
67 Zane KE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2021;13:5430. [PMID: 34771593 DOI: 10.3390/cancers13215430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
68 Swersky A, Kulik L, Kalyan A, Grace K, Caicedo JC, Lewandowski RJ, Salem R. Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Semin Intervent Radiol 2021;38:432-7. [PMID: 34629710 DOI: 10.1055/s-0041-1735528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 De la Garza-Ramos C, Toskich BB. Radioembolization for the Treatment of Hepatocellular Carcinoma: The Road to Personalized Dosimetry and Ablative Practice. Semin Intervent Radiol 2021;38:466-71. [PMID: 34629715 DOI: 10.1055/s-0041-1735571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Laidlaw GL, Johnson GE. Recognizing and Managing Adverse Events in Y-90 Radioembolization. Semin Intervent Radiol 2021;38:453-9. [PMID: 34629713 DOI: 10.1055/s-0041-1735617] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Prachanronarong K, Kim E. Radiation Segmentectomy. Semin Intervent Radiol 2021;38:425-31. [PMID: 34629709 DOI: 10.1055/s-0041-1735529] [Reference Citation Analysis]
72 Sivananthan G, Tabori NE. Principles of Radioembolization. Semin Intervent Radiol 2021;38:393-6. [PMID: 34629704 DOI: 10.1055/s-0041-1735606] [Reference Citation Analysis]
73 Sivananthan G, Tabori NE. Principles of Radioembolization. Semin Intervent Radiol 2021;38:393-6. [PMID: 34629704 DOI: 10.1055/s-0041-1735606] [Reference Citation Analysis]
74 Parikh ND, Pillai A. Recent Advances in Hepatocellular Carcinoma Treatment. Clin Gastroenterol Hepatol 2021;19:2020-4. [PMID: 34116048 DOI: 10.1016/j.cgh.2021.05.045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
75 Qadan M, Fong ZV, Delman AM, Gabr A, Salem R, Shah SA. Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma. J Gastrointest Surg 2021;25:2690-9. [PMID: 34345997 DOI: 10.1007/s11605-021-05095-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
76 Bargellini I, Boni G, Traino AC, Bozzi E, Lorenzoni G, Bianchi F, Cervelli R, Depalo T, Crocetti L, Volterrani D, Cioni R. Management of Liver Tumors during the COVID-19 Pandemic: The Added Value of Selective Internal Radiation Therapy (SIRT). J Clin Med 2021;10:4315. [PMID: 34640332 DOI: 10.3390/jcm10194315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Zhou W, Sze DY. Gastric Outlet Obstruction Following Radioembolization: Extrahepatic Complication from Proximity to a Superficial Hepatic Tumor Treated with an Ablative Dose. J Vasc Interv Radiol 2021;32:1699-701. [PMID: 34534651 DOI: 10.1016/j.jvir.2021.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Kim GH, Kim JH, Kim PH, Chu HH, Gwon DI, Ko HK. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean J Radiol 2021;22:1822-33. [PMID: 34431250 DOI: 10.3348/kjr.2021.0229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
79 De la Garza-Ramos C, Overfield CJ, Montazeri SA, Liou H, Paz-Fumagalli R, Frey GT, McKinney JM, Ritchie CA, Devcic Z, Lewis AR, Harnois DM, Patel T, Toskich BB. Biochemical Safety of Ablative Yttrium-90 Radioembolization for Hepatocellular Carcinoma as a Function of Percent Liver Treated. J Hepatocell Carcinoma 2021;8:861-70. [PMID: 34368021 DOI: 10.2147/JHC.S319215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
80 Kim HC, Choi JW, Lee M, Kim YJ, Paeng JC, Chung JW. Lung Shunt Reduction for Yttrium-90 Radioembolization: Chemoembolization Versus Radioembolization. In Vivo 2021;35:2305-12. [PMID: 34182510 DOI: 10.21873/invivo.12504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2021;13:2984. [PMID: 34203692 DOI: 10.3390/cancers13122984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]